Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Bevacizumab and Pemetrexed in First-Line Malignant Pleural Mesothelioma
NCT00604461Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2007
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in malignant pleural mesothelioma (MPM), sponsored by Moffitt Cancer Center. Primary endpoint: Partial Response at 12 months. Started Oct 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00604461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604461.